Non-invasive tech Cognilum is a home-based, non-invasive neurotherapeutic solution combining wearable near-infrared light therapy with an AI-driven platform, presenting a compelling sales angle to hospitals, clinics, and payer networks seeking innovative autism interventions.

Payer cost-saver The description highlights potential reductions in special education needs and lifelong residential care costs, offering a strong value proposition for government programs and private payers focused on total cost of care and long-term savings.

Early access Publicized early access waitlists and ongoing device development signals a momentum window for pilots or regional launches, enabling BD to target early adopter clinics, school districts, and autism-focused research centers.

Clinical collaboration Past partnerships with neurology-focused companies and mention of clinical trial plans provide entry points for co-development deals, sponsored studies, and data-sharing collaborations that can drive validation and adoption.

Small but scalable Current team size and revenue indicate a lean operation with room for scalable partnerships, turnkey implementation, and OEM/white-label opportunities with larger medical device distributors seeking expansion into pediatric neurotherapies.